Reach further, in an Open Access Journal Endocrinology, Diabetes & Metabolism Case Reports

ISSN 1470-3947 (print)
ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology

Published by BioScientifica
Endocrine Abstracts (2012) 29 P538 

The burden of disease in elderly people with IFG

H. Lutgers1, L. Campbell1,2, B. Baune5, H. Brodaty3, J. Trollor3, P. Sachdev3,4 & K. Samaras1,2

Author affiliations

Introduction: The prevalence of impaired fasting glucose (IFG) in the elderly approaches 50% in some community-dwelling cohorts. We examined whether IFG is associated with a higher burden of disease, cardiovascular risk factors and circulating low-grade inflammation than in normoglycemic elderly people.

Methods/Design: Cross-sectional data of 929 participants of the Sydney Memory and Aging Study (MAS) were examined. MAS is a population-derived cohort of community-dwelling adults aged 70–90 years. Normoglycemic (NG) and IFG participants were compared using contingency tables and the Chi-square test. Logistic regression and ANCOVA analyses were performed adjusted for age, sex and Body Mass Index (BMI).

Results: Mean age was 78.6 (±4.7) years; 47% had IFG, 12% had diagnosed type 2 diabetes and 4% previously undiagnosed type 2 diabetes. There were proportionately more males with IFG compared to NG (49% vs 37% males, P<0.001). As expected, BMI was higher in IFG compared to NG subjects (27.4 kg/m2 vs 26.1 kg/m2, P<0.001). Hypertension and hyperlipidemia was equally distributed (62% and 60% in IFG vs. 57% and 56% in NG), although lipid-lowering drugs had been more frequently prescribed in IFG (55% vs 42%, P<0.001). After adjustment for covariates, rates of stroke, cardiac disease, myocardial infarction, kidney disease or any cancer were similar between participants with IFG and normal fasting glucose. However, PAI-1 (83.7 vs. 79.8 ng/ml, P<0.05), IL-8 (21.8 vs. 18.6 pg/ml, P<0.01), IL-12p70 (3.64 vs 3.40 pg/ml, P<0.05) and products of oxidative metabolism (urate [0.35 vs. 0.32 mmol/l, P<0.001] and malondialdehyde [13.4 vs. 12.8 μmol/l, P<0.001]), were all significantly higher in IFG.

Conclusion: In this cohort of community-dwelling elderly, IFG was not associated with an increased burden of disease cross-sectionally. Prospective data are required to elucidate whether the moderately increased markers of inflammation accompanying IFG in this population adversely affect health outcomes during residual life span.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This work was supported, however funding details unavailable.

This Issue/Conference

Article tools

My recently viewed abstracts

My recent searches